This is the authors' abstract. We don't add key points for this paper.
The development of biologic agents has provided rheumatologists with a variety of new and effective treatment options. The success of early biologics, especially etanercept and infliximab for the treatment of rheumatoid arthritis, has spurred research into novel targets for the management of systemic inflammatory and autoimmune diseases. In addition, existing biologics approved for use in other diseases, such as rituximab, are now under study for the treatment of new indications. This article reviews ongoing research on the treatment of rheumatic diseases with new and existing biologic agents.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shanahan et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: